JP2006514021A - Ｊａｎｕｓチロシンキナーゼ３（Ｊａｋ３）を選択的に阻害するための方法 - Google Patents

Ｊａｎｕｓチロシンキナーゼ３（Ｊａｋ３）を選択的に阻害するための方法 Download PDF

Info

Publication number
JP2006514021A
JP2006514021A JP2004559442A JP2004559442A JP2006514021A JP 2006514021 A JP2006514021 A JP 2006514021A JP 2004559442 A JP2004559442 A JP 2004559442A JP 2004559442 A JP2004559442 A JP 2004559442A JP 2006514021 A JP2006514021 A JP 2006514021A
Authority
JP
Japan
Prior art keywords
jak3
compound
cell
activity
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004559442A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514021A5 (https=
Inventor
カーケン，ロバート，エイ．
カーン，バリー，ディー．
ステプコウスキ，スタニスロー，エム．
プリーブ，ウォルデマー
フォクト，イザベラ
コシンスキ，シモン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2006514021A publication Critical patent/JP2006514021A/ja
Publication of JP2006514021A5 publication Critical patent/JP2006514021A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/04—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
    • C07C225/08—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • C07C225/12—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings with doubly-bound oxygen atoms bound to carbon atoms being part of rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2004559442A 2002-12-09 2003-12-09 Ｊａｎｕｓチロシンキナーゼ３（Ｊａｋ３）を選択的に阻害するための方法 Pending JP2006514021A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43185102P 2002-12-09 2002-12-09
PCT/US2003/038993 WO2004052359A1 (en) 2002-12-09 2003-12-09 Methods for selectively inhibiting janus tyrosine kinase 3 (jak3)

Publications (2)

Publication Number Publication Date
JP2006514021A true JP2006514021A (ja) 2006-04-27
JP2006514021A5 JP2006514021A5 (https=) 2006-12-07

Family

ID=32507812

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004559442A Pending JP2006514021A (ja) 2002-12-09 2003-12-09 Ｊａｎｕｓチロシンキナーゼ３（Ｊａｋ３）を選択的に阻害するための方法

Country Status (17)

Country Link
US (2) US7365096B2 (https=)
EP (1) EP1578411A4 (https=)
JP (1) JP2006514021A (https=)
KR (1) KR20050084224A (https=)
CN (1) CN1747729A (https=)
AU (1) AU2003297740B2 (https=)
BR (1) BR0317099A (https=)
CA (1) CA2506432A1 (https=)
EC (1) ECSP055843A (https=)
HU (1) HUP0500844A2 (https=)
MX (1) MXPA05006133A (https=)
NO (1) NO20052497L (https=)
NZ (1) NZ540427A (https=)
PL (1) PL376844A1 (https=)
RU (1) RU2005121672A (https=)
WO (1) WO2004052359A1 (https=)
ZA (1) ZA200504163B (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7943800B2 (en) 2003-03-28 2011-05-17 Sloan-Kettering Institute For Cancer Research Migrastatin analogs and uses thereof
WO2005012294A1 (en) 2003-07-30 2005-02-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
AU2005237254B2 (en) * 2004-05-03 2010-02-04 Novartis Ag Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor
JP5149001B2 (ja) 2004-05-25 2013-02-20 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ 癌の処置におけるマイグラスタチンアナログ
US8188141B2 (en) 2004-09-23 2012-05-29 Sloan-Kettering Institute For Cancer Research Isomigrastatin analogs in the treatment of cancer
GB0507918D0 (en) 2005-04-19 2005-05-25 Novartis Ag Organic compounds
EP1883302A4 (en) * 2005-05-03 2009-05-20 Rigel Pharmaceuticals Inc JAK KINASE HEMMER AND ITS USE
PL1940465T3 (pl) 2005-10-26 2013-01-31 Novartis Ag Nowe zastosowanie przeciwciał anty-IL-1beta
NO20220050A1 (no) 2005-11-21 2008-08-12 Novartis Ag Neuroendokrin tumorbehandling
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
CN104873972A (zh) 2007-05-29 2015-09-02 诺华股份有限公司 抗IL-1β治疗的新适应症
JP2011515068A (ja) 2007-11-08 2011-05-19 ノバルティス アーゲー 慢性／硬化性同種移植腎症に対する遺伝子発現シグネチャー
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
WO2011006119A2 (en) 2009-07-09 2011-01-13 The Scripps Research Institute Gene expression profiles associated with chronic allograft nephropathy
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
US9018006B2 (en) 2010-07-23 2015-04-28 The University Of Toledo Stable Tregs and related materials and methods
KR20140025530A (ko) 2011-06-27 2014-03-04 노파르티스 아게 테트라히드로-피리도-피리미딘 유도체의 고체 형태 및 염
ES2548414T3 (es) 2011-07-08 2015-10-16 Novartis Ag Novedosos derivados de pirrolo pirimidina
CN103987699A (zh) 2011-10-21 2014-08-13 诺华股份有限公司 作为pi3k调节剂的喹唑啉衍生物
US20140348848A1 (en) 2011-12-02 2014-11-27 Dhananjay Kaul Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
EP2790705B1 (en) 2011-12-15 2017-12-06 Novartis AG Use of inhibitors of the activity or function of pi3k
JO3398B1 (ar) 2011-12-22 2019-10-20 Novartis Ag مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي
EP2794594A1 (en) 2011-12-22 2014-10-29 Novartis AG Quinoline derivatives
WO2013148638A2 (en) * 2012-03-26 2013-10-03 Ep Pharma, Inc. Compositions and methods related to inhibitors of jak kinase
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
WO2015179773A1 (en) 2014-05-22 2015-11-26 The Scripps Research Institute Tissue molecular signatures of kidney transplant rejections
KR20160060100A (ko) 2013-09-22 2016-05-27 칼리토르 사이언시즈, 엘엘씨 치환된 아미노피리미딘 화합물 및 이용 방법
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
BR112016024484A2 (pt) 2014-04-24 2017-08-15 Novartis Ag derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase
CA2945212A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
US9862711B2 (en) 2014-04-24 2018-01-09 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
US11104951B2 (en) 2014-05-22 2021-08-31 The Scripps Research Institute Molecular signatures for distinguishing liver transplant rejections or injuries
CN104090115B (zh) * 2014-07-10 2016-01-13 上海益诺思生物技术有限公司 次级t细胞依赖抗体反应检测外源性化合物免疫抑制方法
KR102737185B1 (ko) 2018-01-20 2024-12-05 선샤인 레이크 파르마 컴퍼니 리미티드 치환된 아미노피리미딘 화합물 및 이의 사용 방법
WO2020067887A1 (en) 2018-09-24 2020-04-02 Erasmus University Medical Center Rotterdam Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses
CN113840821A (zh) 2019-05-23 2021-12-24 诺华股份有限公司 Btk抑制剂的晶型

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA712187A (en) * 1965-06-22 J. C. Buisson Paul 2-(2'-oxo-1'-cyclododecyl) acetic acid, the salts thereof, and process of preparing same
FR1466205A (fr) * 1960-04-01 1967-01-20 Chimie Atomistique Acide 1-cétocyclododécyl-2-acétique, ses sels et leur procédé de préparation
AU566673B2 (en) 1983-09-15 1987-10-29 F. Hoffmann-La Roche Ag Phenethylamine derivatives
US6136595A (en) * 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
KR20010089171A (ko) 1998-08-21 2001-09-29 추후제출 퀴나졸린 유도체
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
CA2392554A1 (en) * 1999-11-30 2001-06-28 Parker Hughes Institute Inhibitors of thrombin induced platelet aggregation
MY128450A (en) 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
CA2326952A1 (en) 2000-11-27 2002-05-27 The Hospital For Sick Children T cell protein tyrosine phosphatase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6010021948, ＤＩＭＭＯＣＫ， ＪＲ ｅｔ ａｌ．, "Ｓｙｎｔｈｅｓｉｓ ａｎｄ ｃｙｔｏｔｏｘｉｃ ｅｖａｌｕａｔｉｏｎ ｏｆ ｓｏｍｅ Ｍａｎｎｉｃｈ ｂａｓｅｓ ｏｆ ａｌｉｃｙｃｌｉｃ ｋｅｔｏｎｅｓ", Ｐｈａｒｍａｚｉｅ, 1995, Ｖｏｌ．５０， Ｎｏ．１, ｐ．６６８−７１ *
JPN6010021950, ＤＩＭＭＯＣＫ， ＪＲ ｅｔ ａｌ．, "Ｅｖａｌｕａｔｉｏｎ ｏｆ ｓｏｍｅ Ｍａｎｎｉｃｈ ｂａｓｅｓ ｏｆ ｃｙｃｌｏａｌｋａｎｏｎｅｓ ａｎｄ ｒｅｌａｔｅｄ ｃｏｍｐｏｕｎｄｓ ｆｏｒ ｃｙｔｏｔｏｘｉｃ ａｃｔｉｖｉｔｙ", Ｅｕｒ． Ｊ． Ｍｅｄ． Ｃｈｅｍ．, 1993, Ｖｏｌ．２８， Ｎｏ．４, ｐ．３１３−２２ *

Also Published As

Publication number Publication date
BR0317099A (pt) 2005-10-25
NZ540427A (en) 2008-04-30
AU2003297740A1 (en) 2004-06-30
NO20052497D0 (no) 2005-05-24
NO20052497L (no) 2005-09-02
MXPA05006133A (es) 2006-03-09
RU2005121672A (ru) 2005-11-20
CN1747729A (zh) 2006-03-15
EP1578411A1 (en) 2005-09-28
EP1578411A4 (en) 2007-05-02
WO2004052359A1 (en) 2004-06-24
US7365096B2 (en) 2008-04-29
HUP0500844A2 (en) 2007-08-28
US7928062B2 (en) 2011-04-19
KR20050084224A (ko) 2005-08-26
AU2003297740A2 (en) 2004-06-30
ECSP055843A (es) 2005-11-22
CA2506432A1 (en) 2004-06-24
AU2003297740B2 (en) 2008-09-11
US20080167220A1 (en) 2008-07-10
ZA200504163B (en) 2007-03-28
US20050203177A1 (en) 2005-09-15
PL376844A1 (pl) 2006-01-09

Similar Documents

Publication Publication Date Title
JP2006514021A (ja) Ｊａｎｕｓチロシンキナーゼ３（Ｊａｋ３）を選択的に阻害するための方法
Macián et al. Gene expression elicited by NFAT in the presence or absence of cooperative recruitment of Fos and Jun
AU8282798A (en) Antioxidant enhancement of therapy for hyperproliferative conditions
Deininger Resistance to imatinib: mechanisms and management
RS53372B (sr) Metodi za tretiranje upalnih bolesti
MXPA06013463A (es) Metodos y reactivos para el tratamiento de desordenes inmuno-inflamatorios.
US6071910A (en) Use of agents to treat eosinophil-associated pathologies
KR101915016B1 (ko) 자가포식 향상물질 및 그 용도
Ferro et al. Tumor necrosis factor-alpha activates pulmonary artery endothelial protein kinase C
WO2015054612A1 (en) Treating organ-specific t cell mediated autoimmune diseases
JP2008510784A (ja) プリン及びピリミジンｃｄｋ阻害剤、並びに自己免疫疾患の治療のためのそれらの使用
JP2006519189A (ja) 白内障および緑内障を診断および治療するための、ｓｇｋ遺伝子ファミリーの使用
JP4593271B2 (ja) 抗炎症性組成物および使用の方法
KR20070103499A (ko) 화합물 및 그의 이용
US7429614B2 (en) Medicament containing an effector of the glutathione metabolism together with α-lipoic acid for treating diabetes mellitus
US20220370388A1 (en) Methods for treating microglial dysfunction
EP3924051B1 (en) Composition and method for inhibiting platelet aggregation
WO2022103706A1 (en) Therapeutic small molecules for treatment of pulmonary hypertension
US20170360888A1 (en) Methods for treating inflammatory arthritis
US20260041653A1 (en) An hdac inhibitor for treating cancer with a modified stk11 activity or expression
US20240390372A1 (en) Methods of treating hair-loss disorders with tyk2 inhibitors
KR20070022758A (ko) 면역염증성 질환의 치료 방법 및 시약
JP2016520610A (ja) 網膜変性疾患の治療のための組成物及び方法
EP3360550A1 (en) Molecules and pharmaceutical compositions, in particular for treating a genetic blood disorder
US20080159983A1 (en) Interleukin-15 antagonists for the treatment of anemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061019

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101019